Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
The Oncologist|May 13, 2017
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment OptionsLaurie M Gay, Sungeun Kim, Kyle Fedorchak, et al.
The Oncologist|May 13, 2022
Variable Genomic Landscapes of Advanced Melanomas with Heavy PigmentationRichard S P Huang, Julie Y Tse, Lukas Harries, et al.
Gynecologic Oncology|April 17, 2019
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapiesStéphanie L Gaillard, Kaitlyn J Andreano, Laurie M Gay, et al.
JCO Precision Oncology|May 14, 2026
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian CancerElizabeth M Swisher, Gottfried Konecny, Joshua Cohen, et al.
Oncotargets and Therapy|December 15, 2015
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapyCasey B Williams, Caitlin McMahon, Siraj M Ali, et al.
European Urology Focus|July 21, 2017
Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy ResponseThai H Ho, Toni K Choueiri, Kai Wang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 29, 2020
CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinomaErik A Williams, Meagan Montesion, Radwa Sharaf, et al.
The Oncologist|March 16, 2018
Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care TestingJames H Suh, Alexa B Schrock, Adrienne Johnson, et al.
Journal of Clinical Pathology|August 1, 2014
Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapiesJ S Ross, K Wang, J V Rand, et al.
JCO Precision Oncology|October 5, 2020
<i>CDKN2C</i>-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i>/<i>RB1</i>-Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-CodeletionErik A Williams, Radwa Sharaf, Brennan Decker, et al.
Pageof 16